Observational Study To Assess The Effectiveness Of Tofacitinib In Ulcerative Colitis In Clinical Practice In Sweden

Back to Search
Print
Bookmark Trial

NCT04338204

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Pfizer
Stockholm, , , Sweden
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Ulcerative Colitis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-99 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- The assignment of the patient to tofacitinib is not decided in advance by the protocol but falls within clinical practice and the prescription of the medicine is done according to the SmPC and is clearly separated from the decision to include the patient in the study.

- The patient must sign the informed consent before enrollment in the study. The informed consent permits extraction of data from SWIBREG at baseline and during the duration of the study. For patients not registered in SWIBREG, they must complete all SWIBREG consents and registration at the time of treatment initiation. Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.

- Patients, male or female, must be 18 years old or above.

- The patient must have active disease as confirmed by fecal calprotectin >250 mg/kg or endoscopic assessment corresponding to a Mayo endoscopic subscore ≥2 not more than 2 weeks prior onset to the initiation of tofacitinib treatment.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- The patient is enrolled in a clinical trial in which the treatment of ulcerative
colitis is dictated by a study protocol. If the patient is participating in another
ongoing observational study (non-interventional), the patient may be included in this
observational study.


- Patients that fulfill any of the contraindications according to the latest version of
the SmPC. Any SmPC label updates will be communicated to all study sites.


- For whatever reason the physician feels the patient unsuitable to participate in the
study.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Ulcerative ColitisA Study To Investigate The Safety And Efficacy Properties Of PF-00547659 In Patients With Active Ulcerative Colitis NCT00928681
  1. Brussels,
  2. Bruxelles,
  3. Leuven,
  4. Brno,
  5. Praha 2,
  6. Praha 2,
  7. Aarhus C,
  8. Berlin,
  9. Kiel,
  10. Muenster,
  11. Regensburg,
  12. Oslo,
  13. Nitra,
  14. L'hospitalet Del Llobregat, Barcelona
  15. Majadahonda, Madrid
  16. Barcelona,
  17. Barcelona,
  18. Madrid,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Ulcerative ColitisA Study To Investigate The Safety And Possible Clinical Benefit Of Multistem(r) In Patients With Moderate To Severe Ulcerative Colitis NCT01240915
  1. San Francisco, California
  2. San Francisco, California
  3. Lafayette, Colorado
  4. Lakewood, Colorado
  5. Littleton, Colorado
  6. Washington, District of Columbia
  7. Clearwater, Florida
  8. Clearwater, Florida
  9. Clearwater, Florida
  10. Jacksonville, Florida
  11. Jacksonville, Florida
  12. South Miami, Florida
  13. Chicago, Illinois
  14. Topeka, Kansas
  15. Louisville, Kentucky
  16. Louisville, Kentucky
  17. Chevy Chase, Maryland
  18. Towson, Maryland
  19. Chesterfield, Michigan
  20. Troy, Michigan
  21. Utica, Michigan
  22. Columbia, Missouri
  23. Mexico, Missouri
  24. New York, New York
  25. New York, New York
  26. New York, New York
  27. Charlotte, North Carolina
  28. Raleigh, North Carolina
  29. Raleigh, North Carolina
  30. Winston Salem, North Carolina
  31. Germantown, Tennessee
  32. Nashville, Tennessee
  33. Norfolk, Virginia
  34. Norfolk, Virginia
  35. Norfolk, Virginia
  36. Richmond, Virginia
  37. Seattle, Washington
  38. Brussels,
  39. Bruxelles,
  40. Edmonton, Alberta
  41. Edmonton, Alberta
  42. Edmonton, Alberta
  43. Montreal, Quebec
  44. Frankfurt am Main,
  45. Halle,
  46. Hannover,
  47. Budapest,
  48. Gyula,
  49. Mosonmagyarovar,
  50. Szekszard,
  51. Milano,
  52. Padova,
  53. Roma,
  54. Bratislava,
  55. Trnava,
  56. Goteborg,
  57. Stockholm,
  58. Uppsala,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Ulcerative ColitisA Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis NCT01465763
  1. Mobile, Alabama
  2. Mobile, Alabama
  3. La Jolla, California
  4. La Jolla, California
  5. La Jolla, California
  6. Los Angeles, California
  7. Los Angeles, California
  8. Los Angeles, California
  9. Los Angeles, California
  10. Los Angeles, California
  11. Palm Springs, California
  12. Palm Springs, California
  13. Palm Springs, California
  14. Rancho Mirage, California
  15. San Diego, California
  16. San Diego, California
  17. San Diego, California
  18. Guilford, Connecticut
  19. Hamden, Connecticut
  20. Hamden, Connecticut
  21. Hamden, Connecticut
  22. Altamonte Springs, Florida
  23. Maitland, Florida
  24. Maitland, Florida
  25. Maitland, Florida
  26. Orange Park, Florida
  27. Orange Park, Florida
  28. Orlando, Florida
  29. Orlando, Florida
  30. Winter Park, Florida
  31. Zephyrhills, Florida
  32. Alpharetta, Georgia
  33. Atlanta, Georgia
  34. Johns Creek, Georgia
  35. Macon, Georgia
  36. Marietta, Georgia
  37. Suwanee, Georgia
  38. Suwanee, Georgia
  39. Oak Lawn, Illinois
  40. Ann Arbor, Michigan
  41. Ann Arbor, Michigan
  42. Ann Arbor, Michigan
  43. Ann Arbor, Michigan
  44. Ann Arbor, Michigan
  45. Ypsilanti, Michigan
  46. Ypsilanti, Michigan
  47. Ypsilanti, Michigan
  48. Saint Louis, Missouri
  49. Saint Louis, Missouri
  50. Great Neck, New York
  51. Great Neck, New York
  52. New York, New York
  53. New York, New York
  54. New York, New York
  55. New York, New York
  56. New York, New York
  57. New York, New York
  58. New York, New York
  59. Cleveland, Ohio
  60. Mentor, Ohio
  61. Mentor, Ohio
  62. Mentor, Ohio
  63. Houston, Texas
  64. Houston, Texas
  65. Houston, Texas
  66. Houston, Texas
  67. Salt Lake City, Utah
  68. Salt Lake City, Utah
  69. Salt Lake City, Utah
  70. West Jordan, Utah
  71. Milwaukee, Wisconsin
  72. Camperdown, New South Wales
  73. Kingswood, New South Wales
  74. Box Hill, Victoria
  75. Wien,
  76. Leuven,
  77. Calgary, Alberta
  78. Hamilton, Ontario
  79. Hamilton, Ontario
  80. London, Ontario
  81. Montreal, Quebec
  82. Barranquilla, Atlantico
  83. Zadar,
  84. Hradec Kralove,
  85. Praha 4,
  86. Praha 7,
  87. Aalborg,
  88. Aarhus C,
  89. Tallinn,
  90. Tallinn,
  91. Tallinn,
  92. Nantes,
  93. Paris,
  94. Toulouse Cedex 9,
  95. Berlin,
  96. Halle,
  97. Hannover,
  98. Lüneburg,
  99. Budapest,
  100. Pecs,
  101. Szeged,
  102. Vac,
  103. Petah Tikva,
  104. Tel Aviv,
  105. Catanzaro, CZ
  106. Rozzano, Milano
  107. Palermo, PA
  108. Palermo, PA
  109. Aviano,
  110. Milan,
  111. Nagakute, Aichi
  112. Hirosaki, Aomori
  113. Chiba-shi, Chiba
  114. Sakura, Chiba
  115. Kurume, Fukuoka
  116. Sapporo, Hokkaido
  117. Nishinomiya, Hyogo
  118. Higashi-ibaraki-gun, Ibaraki
  119. Kochi-shi, Kochi
  120. Sendai, Miyagi
  121. Takatsuki-shi, Osaka
  122. Otsu-shi, Shiga
  123. Hachioji, Tokyo
  124. Minato-ku, Tokyo
  125. Minato-ku, Tokyo
  126. Shinagawa-ku, Tokyo
  127. Shinagawa-ku, Tokyo
  128. Fukuoka,
  129. Hiroshima,
  130. Kagoshima,
  131. Osaka,
  132. Tokyo,
  133. Tokyo,
  134. Riga,
  135. Riga,
  136. Riga,
  137. Leiden, ZH
  138. Milford, Auckland
  139. Dunedin,
  140. Tauranga,
  141. Bydgoszcz, Kujawsko-pomorskie
  142. Warszawa, Mazowieckie
  143. Lodz,
  144. Wroclaw,
  145. Timisoara, Jud Timis
  146. Pyatigorsk, Stavropol Region
  147. Nizhniy Novgorod,
  148. Novosibirsk,
  149. Novosibirsk,
  150. Novosibirsk,
  151. Saint-Petersburg,
  152. Saint-Petersburg,
  153. Samara,
  154. Samara,
  155. Samara,
  156. St. Petersburg,
  157. Zrenjanin, Serbia, Europe
  158. Belgrade,
  159. Belgrade,
  160. Kragujevac,
  161. Bratislava,
  162. Johannesburg, Gauteng
  163. Cape Town, Western Cape
  164. Barcelona,
  165. Madrid,
  166. Madrid,
  167. Madrid,
  168. Simferopol, Ar Krym
  169. Kharkov,
  170. Kyiv,
  171. Lviv,
  172. Lviv,
  173. Odesa,
  174. Uzhgorod,
  175. Vinnytsia,
  176. Vinnytsia,
  177. Cambridge,
  178. London,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Ulcerative ColitisA Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis NCT01458951
  1. Tucson, Arizona
  2. Tucson, Arizona
  3. Tucson, Arizona
  4. Oceanside, California
  5. San Diego, California
  6. San Diego, California
  7. San Francisco, California
  8. San Francisco, California
  9. Torrance, California
  10. Bristol, Connecticut
  11. Bristol, Connecticut
  12. New Haven, Connecticut
  13. New Haven, Connecticut
  14. Plainville, Connecticut
  15. Crystal River, Florida
  16. Inverness, Florida
  17. Inverness, Florida
  18. Naples, Florida
  19. Port Orange, Florida
  20. Port Orange, Florida
  21. Port Orange, Florida
  22. Port Orange, Florida
  23. Decatur, Georgia
  24. Topeka, Kansas
  25. Shreveport, Louisiana
  26. Shreveport, Louisiana
  27. Shreveport, Louisiana
  28. Chevy Chase, Maryland
  29. Chevy Chase, Maryland
  30. Chesterfield, Michigan
  31. Troy, Michigan
  32. Troy, Michigan
  33. Rochester, Minnesota
  34. Columbia, Missouri
  35. Hannibal, Missouri
  36. Mexico, Missouri
  37. Mexico, Missouri
  38. Lebanon, New Hampshire
  39. Egg Harbor Township, New Jersey
  40. Marlton, New Jersey
  41. Vineland, New Jersey
  42. Voorhees, New Jersey
  43. Rochester, New York
  44. Greenville, North Carolina
  45. Lancaster, Pennsylvania
  46. Nashville, Tennessee
  47. Nashville, Tennessee
  48. Nashville, Tennessee
  49. Nashville, Tennessee
  50. Nashville, Tennessee
  51. Nashville, Tennessee
  52. Arlington, Texas
  53. Austin, Texas
  54. Austin, Texas
  55. Austin, Texas
  56. Houston, Texas
  57. Houston, Texas
  58. Tyler, Texas
  59. Richmond, Virginia
  60. Richmond, Virginia
  61. Richmond, Virginia
  62. Richmond, Virginia
  63. Garran, Australian Capital Territory
  64. Concord, New South Wales
  65. Concord, New South Wales
  66. Liverpool, New South Wales
  67. Clayton, Victoria
  68. Innsbruck,
  69. St. Veit an der Glan,
  70. Antwerpen,
  71. Kortrijk,
  72. Roeselare,
  73. Porto Alegre, Rio Grande do Sul
  74. Edmonton, Alberta
  75. Edmonton, Alberta
  76. Montreal, Quebec
  77. Saskatoon, Saskatchewan
  78. Saskatoon, Saskatchewan
  79. Medellin, Antioquia
  80. Osijek,
  81. Rijeka,
  82. Zagreb,
  83. Strakonice,
  84. Usti nad Labem,
  85. Copenhagen, NV
  86. Hvidovre,
  87. Odense C,
  88. Tallinn,
  89. Tallinn,
  90. Tallinn,
  91. Tallinn,
  92. Tallinn,
  93. Tallinn,
  94. Tallinn,
  95. Tallinn,
  96. Amiens Cedex 1,
  97. Bordeaux cedex,
  98. Clichy Cedex,
  99. Paris Cedex 12,
  100. Reims cedex,
  101. St Priest En Jarez,
  102. Kiel, Schlewig Holstein
  103. Frankfurt,
  104. Minden,
  105. Munich,
  106. Ulm,
  107. Bekescsaba, Europe
  108. Budapest,
  109. Budapest,
  110. Budapest,
  111. Budapest,
  112. Debrecen,
  113. Gyula,
  114. Miskolc,
  115. Mosonmagyarovar,
  116. Haifa,
  117. Holon,
  118. Rehovot,
  119. Guri-si, Gyeonggi-do
  120. Seongnam-si, Gyeonggi-do
  121. Busan,
  122. Incheon,
  123. Seoul,
  124. Seoul,
  125. Seoul,
  126. Seoul,
  127. Seoul,
  128. Daugavpils,
  129. Amsterdam,
  130. Amsterdam,
  131. Groningen,
  132. Christchurch, Canterbury
  133. Auckland,
  134. Hamilton,
  135. Wellington,
  136. Wellington,
  137. Wellington,
  138. Lodz, Iodzkie
  139. Bydgoszcz, Kujawsko-pomorskie
  140. Bialystok, Podlaskie
  141. Tychy, Slaskie
  142. Krakow,
  143. Sopot,
  144. Warszawa,
  145. Bucuresti, Sector 5
  146. jud. Mures,
  147. Moscow, Russia
  148. Yaroslavl, Russia
  149. Yaroslavl, Russia
  150. Moscow,
  151. Moscow,
  152. Novosibirsk,
  153. Saratov,
  154. Yaroslavl,
  155. Belgrade,
  156. Novi Sad,
  157. Novi Sad,
  158. Subotica,
  159. Bratislava,
  160. Nitra,
  161. Nove Mesto Nad Vahom,
  162. Presov,
  163. Cape Town, Western Cape
  164. Cape Town, Western Cape
  165. Claremont, Cape Town, Western Cape
  166. Sabadell, Barcelona
  167. Barcelona,
  168. Taichung,
  169. Taipei City,
  170. Chernivtsi,,
  171. Chernivtsi,
  172. Dnipropetrovsk,
  173. Kharkiv,
  174. Kiev,
  175. Odesa,
  176. Vinnytsya,
  177. Zaporizhzhia,
  178. Zaporizhzhia,
  179. Bristol, England
  180. Harrow, Middlesex
  181. Norwich, Norfolk
  182. Norwich,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title Observational Study To Assess The Effectiveness Of Tofacitinib In Ulcerative Colitis In Clinical Practice In Sweden
Official Title Observational Study of Tofacitinib in Ulcerative Colitis in Sweden (ODEN)
Brief Summary This is a prospective observational study using data from an existing, ongoing National Swedish registery (SWIBREG). This study is designed to assess the effectiveness of tofacitinib treatment on clinical disease activity parameters in patients with ulcerative colitis in Swedish clinical practice.
Detailed Description Not Provided
Study Type Observational
Study Design Observational Model: Cohort
Time Perspective: Retrospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population Patients with a confirmed diagnosis of ulcerative colitis, ?18years of age, with confirmed active disease (biomarker or endoscopy) initiating tofacitinib as per the Swedish summary of product characteristics (SmPC)
Condition Ulcerative Colitis
Intervention Drug: tofacitinib
Observational study
Study Groups/Cohorts Patients prescribed tofacitinib
Patients with a confirmed diagnosis of ulcerative colitis with confirmed active disease (biomarker or endoscopy) initiating tofacitinib as per the Swedish summary of product characteristics (SmPC).
Intervention: Drug: tofacitinib
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Not yet recruiting
Estimated Enrollment
 (submitted: April 4, 2020)		120
Original Estimated Enrollment Same as current
Estimated Study Completion Date March 18, 2025
Estimated Primary Completion Date March 18, 2025   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • The assignment of the patient to tofacitinib is not decided in advance by the protocol but falls within clinical practice and the prescription of the medicine is done according to the SmPC and is clearly separated from the decision to include the patient in the study.
  • The patient must sign the informed consent before enrollment in the study. The informed consent permits extraction of data from SWIBREG at baseline and during the duration of the study. For patients not registered in SWIBREG, they must complete all SWIBREG consents and registration at the time of treatment initiation. Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
  • Patients, male or female, must be 18 years old or above.
  • The patient must have active disease as confirmed by fecal calprotectin >250 mg/kg or endoscopic assessment corresponding to a Mayo endoscopic subscore ?2 not more than 2 weeks prior onset to the initiation of tofacitinib treatment.

Exclusion Criteria:

  • The patient is enrolled in a clinical trial in which the treatment of ulcerative colitis is dictated by a study protocol. If the patient is participating in another ongoing observational study (non-interventional), the patient may be included in this observational study.
  • Patients that fulfill any of the contraindications according to the latest version of the SmPC. Any SmPC label updates will be communicated to all study sites.
  • For whatever reason the physician feels the patient unsuitable to participate in the study.
Sex/Gender
Sexes Eligible for Study:All
Ages 18 Years to 99 Years   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts
Contact: Pfizer CT.gov Call Center1-800-718-1021C[email protected]
Listed Location Countries Sweden
Removed Location Countries  
 
Administrative Information
NCT Number NCT04338204
Other Study ID Numbers A3921366
ODEN ( Other Identifier: Alias Study Number )
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement
Plan to Share IPD:No
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d….
Responsible Party Pfizer
Study Sponsor Pfizer
Collaborators Not Provided
Investigators
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date April 2020